VUMON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vumon, and when can generic versions of Vumon launch?
Vumon is a drug marketed by Hq Speclt Pharma and is included in one NDA.
The generic ingredient in VUMON is teniposide. There are two drug master file entries for this compound. Additional details are available on the teniposide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VUMON?
- What are the global sales for VUMON?
- What is Average Wholesale Price for VUMON?
Summary for VUMON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 62 |
| Patent Applications: | 2,378 |
| DailyMed Link: | VUMON at DailyMed |
US Patents and Regulatory Information for VUMON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hq Speclt Pharma | VUMON | teniposide | INJECTABLE;INJECTION | 020119-001 | Jul 14, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
